and increased demand for Zio AT and Zio Monitor products internationally. The company surpassed a significant milestone with 10 million cumulative patient reports since inception, emphasizing its ...

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results , with sales up 20.3% year on year ...

We presented a retrospective analysis of the rhythm monitor in 2011. [2] Briefly, we deployed the FDA-approved Zio Patch products in three large suburban emergency departments (EDs), permitting ...

Zio XT has been recommended by NICE as an option for people with suspected cardiac arrhythmias who would benefit from ECG monitoring for longer than 24 hours, as a lighter, discreet alternative to ...

“Once again, we have strong real-world evidence that compellingly demonstrates the superiority of Zio’s 14-day, uninterrupted, patch-based monitoring — AVALON extends findings beyond ...

Rhythm Technologies shares are on the rise on first-quarter results that were mixed compared to the Wall Street forecast.

iRhythm Technologies, Inc. has announced findings from the AVALON study, presented at HRS2025, highlighting the effectiveness of its Zio long-term continuous monitoring (LTCM) service in a younger ...

“They reinforce the limitations of Holter-duration monitoring and highlight the value of Zio long-term continuous monitoring up to 14 days. Once again, iRhythm's real-world data are contributing ...

Drawing on data from more than 1.1 million patients who used iRhythm’s Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour ...